# Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

*PRI Rank #17 · Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026/rank-17*

| Field | Value |
| --- | --- |
| Rank | #17 |
| 18m citations | 49 |
| Journal | The Lancet |
| Year | 2024 |
| DOI | 10.1016/s0140-6736(23)02577-1 |
| Corresponding authors | Sobha Sivaprasad |
| Institution | Retina Consultants of Texas, United States |

**Ranking page:** [Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026](https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026)

**Paper link:** [10.1016/s0140-6736(23)02577-1](https://doi.org/10.1016/s0140-6736(23)02577-1)

## Topics

Aflibercept · Diabetic macular edema · Noninferiority trial design · Aflibercept · Extended dosing interval · Best-corrected visual acuity (BCVA) · Central subfield thickness · PHOTON trial · Anti-VEGF therapy · 12-week and 16-week dosing regimens · 48-week efficacy outcomes · phase 2/3 clinical trial

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Retinal Diseases and Treatments Papers, Class of 2026. https://pri.pepkio.com/top-papers/retinal-diseases-and-treatments/2026. Accessed 2026-07-14.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```